EC Number   |
Application |
Reference |
|---|
   3.4.21.42 | drug development |
further probing for cooperativity may be of great value in the development of a peptide inhibitor for the C1s protease in the treatment of inflammatory disease |
696546 |
| 3.4.21.42 | medicine |
angioedema due to acquired C1 esterase deficiency is a rare condition and a non-inflammatory disease characterized by episodes of edema of the mucosa of the upper airway or gastrointestinal tract. Careful evaluation of the acute abdomen in acquired C1 esterase deficiency is very important in the emergency department to distinguish between medical and surgical causes of an acute abdomen |
699214 |
| 3.4.21.42 | medicine |
C1s-INH-248 is a highly selective small molecule inhibitor of complement subcomponent C1s. Blocking the classical complement pathway with a highly specific and potent synthetic inhibitor of the classical C1 complex appears to be an effective mean to preserve ischemic myocardium from injury following reperfusion |
652681 |
| 3.4.21.42 | medicine |
drug combinations of C1 esterase inhibitor with coagulation factor XIII and N-acetylcysteine can reduce the leukocyte adherence in a sepsis model in rats indicating an anti-inflammatory effect of these combinations |
697420 |
| 3.4.21.42 | medicine |
enzyme inhibition with sutimlimab rapidly stopps hemolysis in patients with cold agglutinin disease |
753071 |
| 3.4.21.42 | medicine |
the enzyme represents a pivotal upstream point of control in the classical pathway of complement activation and is therefore likely to be a useful target in the therapeutic intervention of diseases like hereditary angioedema, ischemia-reperfusion injury and acute transplant rejection |
650568 |
| 3.4.21.42 | medicine |
two patients with C1s deficiency or abnormality in a Japanese family that have distinct compound heterozygous genotypes derived from three distinct C1s gene mutations including a novel missense mutation in exon XII, and which share similar symptoms, but which are different from those of previously reported cases |
699344 |
| 3.4.21.42 | pharmacology |
inhibition of the complement pathway is of great therapeutic interest. The C1 complex is a very attractive target for selective inhibition of the classical complement pathway because it is the only member of the classical pathway that does not participate in the other complement pathways |
731904 |
